Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Ngai, Lok Lam
358  Ergebnisse:
Personensuche X
?
1

Impact of hemodilution on flow cytometry based measurable r..:

Tettero, Jesse M. ; Heidinga, Maaike E. ; Mocking, Tim R....
Leukemia.  38 (2024)  3 - p. 630-639 , 2024
Link: https://doi.org/10.1038/..
 
?
2

Optimal Prognostic Threshold for Acute Myeloid Leukemia (AM..:

Rodríguez-Arbolí, Eduardo ; Othus, Megan ; Freeman, Sylvie...
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S9 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Prospective Validation of the Prognostic Relevance of CD34+..:

Ngai, Lok Lam ; Hanekamp, Diana ; Janssen, Fleur...
Blood.  , 2023
Link: https://doi.org/10.1182/..
 
?
4

Measurable residual disease-guided therapy in intermediate-..:

Tettero, Jesse M. ; Ngai, Lok Lam ; Bachas, Costa...
Haematologica.  , 2023
Link: https://doi.org/10.3324/..
 
?
5

Prognostic Significance of Measurable Residual Disease Dete..:

Tettero, Jesse M. ; Buisman, Yara ; Ngai, Lok Lam...
HemaSphere.  7 (2023)  12 - p. e981 , 2023
Link: https://doi.org/10.1097/..
 
?
6

Concordance in measurable residual disease result after fir..:

Tettero, Jesse M. ; Al-Badri, Waleed K. W. ; Ngai, Lok Lam...
Frontiers in Oncology.  12 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
7

Technical Aspects of Flow Cytometry-based Measurable Residu..:

Tettero, Jesse M. ; Freeman, Sylvie ; Buecklein, Veit...
HemaSphere.  6 (2022)  1 - p. e676 , 2022
Link: https://doi.org/10.1097/..
 
?
8

Measurable residual disease as a biomarker in acute myeloid..:

Walter, Roland B. ; Ofran, Yishai ; Wierzbowska, Agnieszka...
Leukemia.  35 (2021)  6 - p. 1529-1538 , 2021
Link: https://doi.org/10.1038/..
 
?
9

2021 Update on MRD in acute myeloid leukemia: a consensus d..:

Heuser, Michael ; Freeman, Sylvie D. ; Ossenkoppele, Gert J....
Blood.  138 (2021)  26 - p. 2753-2767 , 2021
Link: https://doi.org/10.1182/..
 
?
10

MRD Tailored Therapy in AML: What We Have Learned So Far:

Ngai, Lok Lam ; Kelder, Angèle ; Janssen, Jeroen J. W. M...
Frontiers in Oncology.  10 (2021)  - p. , 2021
Link: https://doi.org/10.3389/..
 
?
11

Bimodal expression of potential drug target CLL‐1 (CLEC12A)..:

Ngai, Lok Lam ; Ma, Connie Y. ; Maguire, Orla...
European Journal of Haematology.  107 (2021)  3 - p. 343-353 , 2021
Link: https://doi.org/10.1111/..
 
?
12

Quality of Life During Palliative Systemic Therapy for Esop..:

van Kleef, Jessy Joy ; ter Veer, Emil ; van den Boorn, Héctor G...
JNCI: Journal of the National Cancer Institute.  , 2019
Link: https://doi.org/10.1093/..
 
?
13

TOXview: a novel graphical presentation of cancer treatment..:

Ngai, Lok Lam ; ter Veer, Emil ; van den Boorn, Héctor G....
Acta Oncologica.  58 (2019)  8 - p. 1138-1148 , 2019
Link: https://doi.org/10.1080/..
 
?
14

Capecitabine, 5-fluorouracil and S-1 based regimens for pre..:

ter Veer, Emil ; Ngai, Lok Lam ; Valkenhoef, Gert van...
Scientific Reports.  7 (2017)  1 - p. , 2017
Link: https://doi.org/10.1038/..
 
?
15

The efficacy and safety of S-1-based regimens in the first-..:

ter Veer, Emil ; Mohammad, Nadia Haj ; Lodder, Paul...
Gastric Cancer.  19 (2016)  3 - p. 696-712 , 2016
Link: https://doi.org/10.1007/..
 
1-15